Redeye provides a more in-depth review of Episurf Medical’s Q3 report. On the back of announcements made during the quarter, we have made some downward adjustments to our sales estimates and now factor in a capital injection in H2 2025e. Our financial estimates revision and the inclusion of a capital injection renders a drastically lower fair value range.